Biotechnology University Research Law In Russia.

1. Introduction

Biotechnology University Research Law in Russia refers to the legal framework governing biotechnology research conducted by universities, scientific institutions, laboratories, research centres and academic-industry partnerships.

It regulates the development, testing, financing, ownership, commercialization and ethical supervision of biotechnology research, including:

Genetic engineering and genome editing.

Stem-cell and regenerative medicine research.

Genetically modified organisms (GMOs).

Molecular biology and genetic sequencing.

Pharmaceutical and vaccine development.

Synthetic biology and biotechnology innovation.

Clinical trials and biomedical experimentation.

Research involving human biological materials.

Biotechnology patents and university intellectual property.

International scientific cooperation and technology transfer.

Russian university biotechnology research is not governed by one comprehensive statute. Instead, it is regulated through constitutional provisions, federal legislation, government regulations, scientific research rules, intellectual property laws and international obligations.

The central legal challenge is balancing scientific freedom, public health, research ethics, intellectual property rights, environmental protection and national biosecurity.

2. Constitutional Framework

The Constitution of the Russian Federation provides the foundation for university research and scientific development.

Important constitutional provisions include:

Article 29: Protects freedom of thought, expression and information.

Article 34: Protects lawful economic and entrepreneurial activity.

Article 41: Recognizes the right to health protection and medical assistance.

Article 44: Protects freedom of scientific, technical and other creative activity.

Article 71: Establishes federal authority over important areas including federal property, intellectual property regulation and certain national policy matters.

Legal significance

Article 44 is particularly important because it recognizes scientific and technical creativity as constitutionally protected activity.

Universities can conduct legitimate biotechnology research, publish scientific results, develop inventions and collaborate with commercial research organizations.

However, scientific freedom is not unlimited. Research may be restricted by laws concerning public health, biological safety, environmental protection, personal information and national security.

A university cannot rely on academic freedom to avoid mandatory licensing, safety inspections or ethical requirements.

3. Principal Federal Legislation Governing University Biotechnology Research

Several federal statutes determine how Russian universities may conduct biotechnology research.

A. Federal Law No. 127-FZ of 23 August 1996 – Science and State Scientific and Technical Policy

This is the principal general legislation governing scientific research in Russia.

It regulates:

The legal status of scientific organizations.

University research activities.

Government funding of scientific projects.

Scientific research agreements.

Research commercialization.

Scientific cooperation between universities and industry.

Rights and responsibilities of researchers.

Article 3 recognizes scientific and technical activity by individuals and legal entities and provides for freedom in choosing research directions and methods, subject to Russian law.

Application to biotechnology universities:

A Russian university may establish molecular biology laboratories, undertake genome research, develop biotechnology products and collaborate with pharmaceutical companies.

However, the institution must comply with applicable safety, funding, research and intellectual property requirements.

Consultant Plus+2

B. Federal Law No. 273-FZ of 29 December 2012 – Education in the Russian Federation

This legislation governs educational institutions, including universities conducting scientific research.

Its relevance includes:

University institutional autonomy.

Research-based higher education.

Academic freedom.

Rights and responsibilities of researchers and students.

Educational and research infrastructure.

University cooperation with external scientific organizations.

Biotechnology application:

A university may establish:

Genetic engineering research departments.

Biotechnology laboratories.

Pharmaceutical research centres.

Biomedical engineering institutes.

Graduate-level molecular biology programmes.

Research conducted as part of education must nevertheless comply with applicable biological safety and human-subject protections.

C. Federal Law No. 86-FZ of 5 July 1996 – State Regulation of Genetic Engineering Activities

This is one of the most important laws for biotechnology research.

It regulates genetically engineered activities, environmental protection, ecological safety and human health protection. Its framework is particularly relevant to research involving genetically engineered organisms.

Important subjects include:

Genetic engineering.

Genetically engineered modified organisms.

Biological containment.

Environmental release.

Registration of relevant GMOs.

Liability for violations.

University application

Suppose a Russian university develops genetically modified microorganisms for pharmaceutical research.

The university must determine whether its activities fall within the law's requirements and whether any registration, containment or other regulatory obligations apply.

A particularly important distinction is between contained laboratory research and releasing genetically modified organisms into the environment.

The law does not mean that every laboratory experiment involving genetic engineering requires the same registration procedure as environmental release.

cis-legislation.com+2

Important 2026 development

Federal Law No. 43-FZ of 20 February 2026 amended Federal Law No. 86-FZ. The amendments address the legal framework for transferring human genetic data and define human genetic data and population genetic or immunological research.

The amended provisions are particularly relevant to universities conducting:

Population genetics research.

Genetic sequencing.

Human genome studies.

Genetic epidemiology.

International genetic-data collaborations.

The amended version of Federal Law No. 86-FZ took effect on 1 September 2026, so it is relevant to the legal position as of November 2026.

cis-legislation.com+1

 

D. Federal Law No. 152-FZ of 27 July 2006 – Personal Data

University biotechnology research frequently involves personal and genetic information.

Examples include:

DNA sequencing results.

Patient genetic profiles.

Family genetic histories.

Clinical research records.

Biological sample identification data.

Health-related information.

Universities must comply with personal-data processing requirements, including lawful processing, appropriate safeguards and applicable consent requirements.

Genetic information can be particularly sensitive because it may reveal information about both the research participant and biological relatives.

The 2026 amendments to Federal Law No. 86-FZ make the specific regulation of human genetic-data transfers an especially important additional consideration.

E. Federal Law No. 323-FZ of 21 November 2011 – Fundamentals of Health Protection

This law becomes important when university research involves patients, human experimentation or medical applications.

It addresses:

Patient rights.

Medical confidentiality.

Informed consent.

Medical research.

Healthcare professional responsibilities.

Protection of human dignity and health.

Article 20 is particularly relevant to informed voluntary consent in medical intervention.

Article 21 of the Russian Constitution separately protects individuals against medical, scientific and other experiments without voluntary consent.

F. Federal Law No. 180-FZ of 23 June 2016 – Biomedical Cellular Products

This statute governs the development, preclinical research, clinical trials, registration, manufacture and use of biomedical cellular products intended for medical purposes.

It is relevant to:

Regenerative medicine.

Cellular therapies.

Advanced biomedical products.

Cell-based therapeutic development.

Important distinction: Article 1(2) excludes certain activities involving human cells and tissues for scientific and educational purposes from this law's scope. Therefore, ordinary academic cell research must not automatically be treated as the regulated commercial or clinical circulation of biomedical cellular products.

A university moving from laboratory research to a therapeutic product or clinical application must assess the relevant regulatory regime separately.

cis-legislation.com+1

 

G. Federal Law No. 61-FZ of 12 April 2010 – Circulation of Medicines

This legislation becomes relevant when university research develops a pharmaceutical product.

It regulates:

Pharmaceutical development.

Preclinical research.

Clinical trials.

State registration of medicines.

Manufacturing.

Quality control.

Circulation of medicinal products.

A university developing a biotechnology-based vaccine or recombinant protein medicine cannot treat academic research approval as equivalent to authorization to market the product.

4. Institutional Governance of University Biotechnology Laboratories

Russian universities must maintain institutional systems that ensure lawful research operations.

A. Laboratory authorization and supervision

A university should establish procedures for:

Research project approval.

Laboratory safety assessments.

Biological-material handling.

Storage and transportation of samples.

Personnel training.

Equipment maintenance.

Research documentation.

Incident reporting.

Depending on the activity, sanitary, environmental, medical, genetic-engineering and other regulatory requirements may apply.

B. Biosafety governance

Biotechnology research may involve bacteria, viruses, recombinant organisms and biological materials.

Universities should assess:

Biological hazard classification.

Laboratory containment requirements.

Exposure risks.

Waste disposal.

Accidental release.

Staff protection.

Emergency response.

For example, a university conducting research involving a potentially hazardous microorganism must establish appropriate containment and handling procedures.

C. Research ethics committees

Research involving human participants requires appropriate ethical and legal safeguards.

An institutional ethics committee may assess:

Scientific justification.

Participant selection.

Informed consent documents.

Risks and benefits.

Privacy safeguards.

Vulnerable research participants.

Biological sample collection and storage.

Ethical review does not replace statutory authorization where authorization is required.

D. University research accountability

Institutional accountability can arise from:

Negligent laboratory supervision.

Unauthorized experimentation.

Improper handling of biological materials.

Misuse of government research grants.

Breaches of confidentiality.

Research misconduct.

Environmental damage.

Both the university and responsible individuals may face consequences depending on their respective conduct and applicable legislation.

5. University Research Funding and Government Accountability

Russian biotechnology research may be financed through:

Federal government research programmes.

University research budgets.

Government grants.

Research foundations.

Pharmaceutical industry partnerships.

Commercial biotechnology investment.

International scientific cooperation.

The legal relationship between the funding institution and university may be governed by grant conditions, public procurement rules, research agreements and civil legislation.

Important legal issues

A. Misuse of research grants

Universities must use public research funding according to the approved purposes and financial conditions.

B. Scientific failure

A failed experiment does not automatically constitute financial misconduct. Scientific research involves uncertainty, and the legal consequences depend on the funding agreement, actual expenditure and compliance with reporting requirements.

C. Research reporting

Universities may be required to submit:

Scientific progress reports.

Financial statements.

Experimental findings.

Research deliverables.

Intellectual property disclosures.

D. Audit responsibility

Government-funded research may be subject to financial and institutional oversight.

A university may face recovery claims or other legal consequences if it misuses funds or materially breaches the applicable grant conditions.

6. Intellectual Property Rights in University Biotechnology Research

Intellectual property is one of the most important legal dimensions of biotechnology research in Russia.

The relevant framework is Part IV of the Russian Civil Code.

The principal protected interests include:

Patents for biotechnology inventions.

Scientific publications and research materials.

Software used in biological analysis.

Laboratory-developed technologies.

Trade secrets and confidential research information.

Rights of university researchers and inventors.

A. Ownership of biotechnology inventions

Under Articles 1345–1347 of the Civil Code, patent rights include the exclusive right and the right of attribution.

For university research, the key question is whether an invention qualifies as a service invention.

Article 1370 regulates inventions created by employees in connection with their employment duties or a specific assignment from their employer.

For example:

A university researcher develops a new gene-sequencing technique using university equipment while performing an assigned research project.

The university and researcher must determine ownership under the statutory rules governing service inventions.

The researcher retains legally protected authorship interests, while the employer may acquire the right to obtain a patent under the applicable conditions.

B. Biotechnology patentability

Potential biotechnology inventions include:

Recombinant DNA technologies.

Novel pharmaceutical formulations.

Genetic testing technologies.

Laboratory equipment.

Industrial microorganism applications.

Biotechnology manufacturing processes.

Novel methods of biological analysis.

Patentability depends on the statutory requirements, including novelty, inventive step and industrial applicability.

Not every scientific discovery is patentable. A naturally occurring biological substance or discovery, without a qualifying technical invention, cannot automatically be patented.

C. University-industry research agreements

Universities frequently collaborate with pharmaceutical companies and biotechnology enterprises.

Such agreements should specify:

Ownership of pre-existing intellectual property.

Ownership of newly developed inventions.

Patent application responsibilities.

Research publication rights.

Confidentiality obligations.

Commercial licensing.

Revenue-sharing arrangements.

Access to research materials.

Disputes may arise when a university researcher creates an invention using jointly financed equipment or when an industrial partner attempts to commercialize research without respecting the agreed ownership arrangements.

rospatent.gov.ru+2

7. Human Biological Materials and University Research

Human biological materials are essential to modern biotechnology.

Examples include:

Blood samples.

Tissue samples.

Stem cells.

DNA samples.

Tumour specimens.

Reproductive biological materials.

Russian universities must consider the legal basis for collecting, storing, analysing and using these materials.

A. Informed consent

Human research must respect voluntary participation and informed consent where required.

The participant should receive information about:

The purpose of the research.

The nature of the procedures.

Potential risks.

The use of biological samples.

Relevant data processing.

The possibility of future research use.

B. Genetic privacy

Genetic data can reveal highly personal information.

A university must consider whether its research involves identifiable personal data and whether applicable data-protection and genetic-data requirements are satisfied.

C. Secondary use of samples

Suppose a university collects blood samples for cancer research and subsequently wishes to use them for population-genetics research.

The university must examine whether the original consent, applicable legal basis, research protocol and genetic-data requirements permit the additional use.

The original collection of a sample does not automatically authorize every future research purpose.

D. International sharing

If a Russian university transfers human genetic data to a foreign research institution, the amended Federal Law No. 86-FZ and applicable personal-data and transfer requirements must be considered.

This is particularly important for international genome databases and collaborative precision-medicine projects.

8. Clinical Trials and University Biotechnology Research

Universities may participate in pharmaceutical and biotechnology clinical trials.

However, academic research and regulated clinical development are legally distinct.

A university conducting preclinical experiments does not automatically have permission to conduct clinical trials.

Main regulatory requirements

Appropriate regulatory authorization.

Ethical review where required.

Informed consent.

Qualified investigators.

Proper research documentation.

Safety monitoring.

Reporting of adverse events.

Compliance with applicable clinical-trial standards.

Example: University vaccine research

Suppose a Russian university develops an experimental vaccine using recombinant biotechnology.

The research may progress through several stages:

Laboratory development.

Preclinical evaluation.

Manufacturing and quality assessment.

Regulatory application for clinical development.

Clinical trials.

State registration where required.

Authorized medical circulation.

Each stage has separate legal and scientific requirements.

9. International Biotechnology Research Cooperation

Russian universities may engage in international research collaborations, subject to applicable Russian legislation and other relevant restrictions.

Examples include:

International genome research.

Joint pharmaceutical development.

Cross-border laboratory cooperation.

Scientific publications.

Biological-material exchange.

Collaborative vaccine research.

Important legal considerations include:

A. Genetic-data transfers: Federal Law No. 86-FZ, as amended in 2026, is particularly relevant to human genetic information.

B. Personal-data transfers: Federal Law No. 152-FZ regulates personal-data processing and cross-border transfers.

C. Export controls: Federal Law No. 183-FZ of 18 July 1999 may become relevant when biotechnology materials, equipment, software or technical information fall within controlled categories.

D. Intellectual property: The university must establish ownership and licensing arrangements for jointly developed inventions.

E. Research contracts: Agreements should address confidentiality, research responsibilities, publication, liability and dispute resolution.

International collaboration does not remove the university's obligations under Russian law.

10. Important Russian Case Laws and Judicial Authorities

Russian courts have not developed a large, specialized body of reported decisions specifically addressing biotechnology research conducted by universities.

Nevertheless, several judicial authorities are useful for understanding the legal principles applicable to university biotechnology research.

It is important to distinguish direct biotechnology decisions from broader intellectual-property and human-rights precedents.

Case 1. Supreme Court of the Russian Federation – GMO Regulatory Violation

Direct biotechnology-related case

Court: Supreme Court of the Russian Federation.

Decision: 19 September 2023.

Case number: 9-АД23-12-К1.

Subject: Use of unregistered genetically modified rapeseed.

Facts:

The dispute involved the use of genetically modified rapeseed containing the CP4 EPSPS genetic element on agricultural land in the Nizhny Novgorod region.

The regulatory authority found that the company had used genetically modified material without the required registration.

The company challenged the administrative penalty.

Legal issue:

Whether the use of genetically modified organisms without the legally required registration constituted an administrative offence.

Decision:

The Supreme Court upheld the earlier decisions and the administrative penalty of RUB 250,000.

The court relied on Article 6.3.1 of the Code of Administrative Offences and the relevant GMO regulatory legislation.

Legal significance for universities:

This decision is important for university agricultural biotechnology laboratories.

It demonstrates that scientific or commercial use of genetically modified organisms must comply with applicable statutory restrictions.

A university cannot assume that research-related activity automatically exempts it from every GMO requirement. The precise statutory exception for examination and research activities must be assessed against the facts.

ГАРАНТ+1

Case 2. Supreme Court Plenary Resolution No. 10 of 23 April 2019

Intellectual-property authority

Court: Supreme Court of the Russian Federation.

Date: 23 April 2019.

Authority: Plenary Resolution No. 10.

Subject: Application of Part IV of the Russian Civil Code.

Legal issue:

How should Russian courts interpret and enforce intellectual property rights?

Principles:

The resolution clarifies the legal nature of intellectual property and the distinction between exclusive rights, authorship rights and other legally recognized intellectual-property interests.

Application to university biotechnology research:

Suppose a university researcher develops a patentable pharmaceutical biotechnology process.

A dispute may arise between the researcher, university and commercial partner concerning:

Inventorship.

Patent ownership.

Exclusive rights.

Licensing.

Remuneration.

The Supreme Court's interpretative guidance is relevant to resolving such disputes.

This is a general intellectual-property authority, not a judgment specifically about biotechnology universities.

OUP Academic+1

 

Case 3. European Court of Human Rights – Avilkina and Others v. Russia

Court: European Court of Human Rights.

Application No.: 1585/09.

Judgment: 6 June 2013.

Subject: Medical confidentiality and disclosure of personal health information.

Facts:

The case concerned disclosure of confidential medical information to prosecutorial authorities without the required justification.

Legal significance:

The Court examined the protection of private life under Article 8 of the European Convention on Human Rights.

Application to university research:

Universities conducting biomedical research should protect patient confidentiality and prevent unjustified disclosure of medical records.

This authority is relevant to the privacy principles surrounding research data, although it is not a judgment concerning university biotechnology experiments.

Case 4. European Court of Human Rights – Roman Zakharov v. Russia

Court: European Court of Human Rights, Grand Chamber.

Application No.: 47143/06.

Judgment: 4 December 2015.

Subject: Privacy and safeguards against secret surveillance.

Legal principle:

The Court examined whether the Russian surveillance framework provided adequate safeguards against arbitrary interference with private life.

Application to biotechnology universities:

The judgment offers a broader privacy-law reference when assessing the protection of sensitive research information, including identifiable genetic and health-related information.

It is not a direct biotechnology or genetic-data judgment.

Important qualification: The European Convention's application to Russia changed following Russia's cessation of membership in the Council of Europe in September 2022. This judgment remains a historical legal authority, but it should not be presented as establishing an ongoing general Convention obligation for Russia in November 2026.

Case 5. European Court of Human Rights – Roman Zakharov v. Russia

Legal significance: Protection of confidential information and safeguards against unauthorized surveillance.

The Grand Chamber judgment is dated 4 December 2015, Application No. 47143/06.

The Court found a violation of Article 8 concerning the Russian system of secret interception of mobile telephone communications.

Application to university biotechnology research:

A university may store large quantities of genetic and medical information. Unauthorized access, surveillance or disclosure can threaten the confidentiality of research participants.

The judgment provides a broader privacy safeguard principle, although it does not directly address genetic databases.

hudoc.echr.coe.int+1

 

Case-law summary

Judicial authorityRelevant legal principle
Supreme Court, 9-АД23-12-К1 (2023)GMO registration and compliance
Supreme Court Plenary Resolution No. 10 (2019)Intellectual property rights
Avilkina v. Russia (2013)Medical confidentiality
Roman Zakharov v. Russia (2015)Privacy and information safeguards

These cases should not be represented as direct precedents on university biotechnology governance. They provide relevant principles from related areas of Russian and European law.

11. Legal Liabilities of Russian Universities

University biotechnology research can generate civil, administrative and criminal liability.

A. Civil liability

A university may face civil claims arising from:

Negligent laboratory operations.

Damage caused by biological materials.

Breach of research agreements.

Patent infringement.

Improper commercialization.

Breach of confidentiality.

B. Administrative liability

Administrative consequences may arise from:

Unauthorized GMO activities.

Violations of sanitary requirements.

Improper handling of regulated biological materials.

Violations of personal-data legislation.

Failure to comply with applicable licensing obligations.

The GMO case discussed above illustrates the potential financial consequences of regulatory non-compliance.

C. Criminal liability

Depending on the facts, criminal liability may arise under relevant provisions of the Russian Criminal Code.

Potential areas include:

Negligent conduct causing serious harm.

Environmental offences.

Violations involving dangerous biological materials.

Illegal disclosure of legally protected information.

Fraud involving research funding.

Criminal liability requires satisfaction of the elements of the relevant offence; an unsuccessful experiment alone is not a criminal offence.

12. Emerging Legal Challenges

Russian university biotechnology research faces several developing legal challenges.

Emerging issuePrincipal legal concern
CRISPR researchGenetic engineering and biosafety
Human genome sequencingGenetic-data protection
Artificial intelligence in biotechnologyData protection and accountability
Stem-cell researchHuman biological materials
Synthetic biologyBiological containment
BioprintingMedical-product regulation
University genetic databasesPrivacy and data security
Biotechnology patentsInventorship and ownership
International researchData transfers and export controls
Pharmaceutical innovationClinical trials and registration

A. CRISPR and genome editing

Universities developing CRISPR technologies must determine whether their activities fall within genetic-engineering, medical, biosafety or other regulatory frameworks.

Research involving human cells and research intended for clinical treatment may be subject to different legal requirements.

B. Artificial intelligence and biotechnology

AI-assisted laboratories create questions concerning:

Scientific accountability.

Accuracy of automated genetic analysis.

Research reproducibility.

Data security.

Patent inventorship.

Responsibility for defective research outputs.

C. Genetic-data commercialization

Commercial use of university-generated genetic information raises questions about consent, lawful processing, intellectual property and the rights of research participants.

D. International research restrictions

International sanctions, export controls, research-funding conditions and restrictions on transferring sensitive genetic information can affect international university partnerships.

13. Practical Example: Biotechnology Research at a Russian University

Consider a hypothetical Russian university establishing a research centre to develop a gene-based treatment for a hereditary disease.

Super-precise CRISPR tool enters US clinical trials for the first time

 

 

2026 Bioinformatics Degree Coursework Explained: What Classes Can You Expect to Take? | Research.com

 

 

Summer Experiential Learning Abroad - NYU Abu Dhabi

 

8

 

The project involves five legal stages.

Stage 1: Institutional establishment

The university establishes a biotechnology research department under the applicable education and science legislation.

Stage 2: Laboratory research

The university develops a research protocol, assesses biological risks and establishes appropriate laboratory safety procedures.

Stage 3: Human genetic research

If researchers collect human samples or process identifiable genetic information, they must assess consent, privacy and applicable genetic-data requirements.

Stage 4: Intellectual property protection

The university determines inventorship, ownership of service inventions and the appropriate patent or confidentiality strategy.

Stage 5: Clinical development

If the research advances into a therapeutic product or clinical trial, the university must comply with the applicable medical and pharmaceutical regulatory framework.

This example demonstrates that university biotechnology research is governed by several connected legal systems rather than a single research authorization.

14. Important Legal Provisions: Quick Reference

LegislationMain subject
Russian Constitution, Article 44Scientific freedom
Federal Law 127-FZ (1996)Science and scientific policy
Federal Law 273-FZ (2012)Education and universities
Federal Law 86-FZ (1996)Genetic engineering
Federal Law 152-FZ (2006)Personal-data protection
Federal Law 323-FZ (2011)Health protection and patient rights
Federal Law 180-FZ (2016)Biomedical cellular products
Federal Law 61-FZ (2010)Medicines
Federal Law 7-FZ (2002)Environmental protection
Federal Law 183-FZ (1999)Export control
Russian Civil Code, Part IVIntellectual property

15. Conclusion

Biotechnology University Research Law in Russia represents an intersection of constitutional law, education law, scientific regulation, environmental law, healthcare law, intellectual property and data protection.

Federal Law No. 127-FZ establishes the general framework for scientific activity, while Federal Law No. 86-FZ regulates important aspects of genetic engineering. Federal Laws Nos. 152-FZ, 323-FZ, 180-FZ and 61-FZ become relevant when university research involves genetic information, human participants, cellular products or pharmaceutical development.

The 2026 amendments to Federal Law No. 86-FZ are particularly significant because they introduce additional legal considerations concerning human genetic information and its transfer.

The judicial authorities discussed above demonstrate that biotechnology universities must consider GMO compliance, scientific intellectual property, medical confidentiality and privacy safeguards.

Ultimately, the Russian legal framework seeks to ensure that university biotechnology research develops within legally established boundaries while protecting human health, scientific interests, biological safety and intellectual property.

16. Recommended Primary Legal Research Sources

For academic dissertations, research papers and legal publications, the following sources are useful:

Federal Law No. 127-FZ – Science and State Scientific and Technical Policy.

Federal Law No. 86-FZ – Genetic Engineering Activities.

Federal Law No. 180-FZ – Biomedical Cellular Products.

Russian Civil Code – Part IV, Intellectual Property.

Supreme Court GMO decision – 9-АД23-12-К1.

Avilkina and Others v. Russia – ECHR judgment.

Roman Zakharov v. Russia – ECHR judgment.

Research note: This is an academic overview, not a substitute for reviewing the complete consolidated Russian legislation, implementing regulations and original Russian-language judgments. The legal framework is discussed as at 18 November 2026. Particular attention should be given to commencement dates and subsequent amendments.

I can also develop the next topic, Biotechnology University Research Ethics Law in Russia – Detailed Explanation With Case Laws, in the same legal-research format.

LawGratis provides pro bono legal aid and resources to empower communities. Join us in making justice reachable for everyone! Follow our community on Instagram, YouTube, Facebook, and LinkedIn.

LEAVE A COMMENT